Nov 9, 2021
CORMEDIX INC. REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Nov 2, 2021
CorMedix Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9
Oct 20, 2021
CORMEDIX INC. ANNOUNCES ABSTRACTS AT UPCOMING CONFERENCES SHOWING PATIENT OUTCOMES AND ECONOMIC BURDEN OF CRBSI
Oct 4, 2021
CORMEDIX INC. ANNOUNCES EXECUTIVE LEADERSHIP CHANGES
Sep 7, 2021
CORMEDIX INC. ANNOUNCES REGULATORY UPDATE
Aug 12, 2021
CORMEDIX INC. REPORTS SECOND QUARTER AND SIX MONTH 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Jul 28, 2021
CorMedix Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12
Jun 10, 2021
CorMedix Inc. Completes Sale of $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program
Jun 9, 2021
CorMedix Inc. to Participate in Fireside Chat at the JMP Securities Life Sciences Conference
May 27, 2021
CorMedix Inc. to Present at the Jefferies Virtual Healthcare Conference
May 13, 2021
CorMedix Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
May 5, 2021
CorMedix Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13
Apr 28, 2021
CORMEDIX INC. TO PARTICIPATE AT THE 7th ANNUAL TRUIST SECURITIES LIFE SCIENCES SUMMIT
Apr 14, 2021
CORMEDIX HAS MEETING WITH FDA ON DEFENCATH CATHETER LOCK SOLUTION NDA
Mar 30, 2021
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Mar 23, 2021
CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update on March 30
Mar 15, 2021
CorMedix Approved to Sell $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program
Mar 8, 2021
CorMedix Inc. to Host Regulatory Update Conference Call
Mar 1, 2021
CORMEDIX RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR DEFENCATH™ CATHETER LOCK SOLUTION
Jan 21, 2021
CORMEDIX INC. TO BEGIN TRADING ON THE NASDAQ STOCK EXCHANGE
